Quest Cap - Co Chair, Stan Bharti
Co Chair, Stan Bharti
Source: Mining Weekly
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Investment company, QuestCap Inc (CSE:QSC) is partnering with the Sinai Health Foundation to develop a diagnostic test for the COVID-19 virus
  • According to the agreement, QuestCap is proving C$500,000 to Sinai Health in exchange for royalties on any projects that reach the market
  • QuestCap also retains the option to develop any resulting IP through a proposed joint venture between the two companies called NewCo
  • QuestCap would assume the costs of maintaining and developing the joint venture, with any profits being split between both parties
  • QuestCap Inc (QSC) is down 8.11 per cent, with shares trading for $0.68 and a market cap of $25.03 million

Investment company, QuestCap Inc, (CSE:QSC) is partnering with the Sinai Health Foundation to develop a diagnostic test for COVID-19.

According to the agreement, QuestCap is providing C$500,000 to Sinai in exchange for royalties on any projects that reach the market.

Furthermore, through the agreement QuestCap has the option to further develop and produce any intellectual property that results from the investment.

However, if QuestCap exercises this option, a further agreement, setting out new terms, will need to be negotiated. A joint venture would emerge out this new agreement called NewCo, through which both companies could maintain a shared interest.

QuestCap would assume all the costs in developing and maintain the new joint venture and its Sinai’s intellectual properties, with profits being split between both parties.

Even before partnering with QuestCap, researchers at Sinai Health, led by Dr. Anne-Claude Gingras, have been developing the test.

Stan Bharti, Co-Chair, QuestCap Inc, believes this is positive and timely step for the company.

“We are enthusiastic about partnering with Dr. Gingras and her team at LTRI as they explore ways to find alternative testing solutions for the COVID-19 virus.

“We are committed to putting our capital to use where we can to aid in the fight against this global pandemic, and this investment illustrates how public and private enterprises can work together in this time of crisis,” he said.

The company was quick to point out that the COVID-19 test is still in early research and development. Therefore, there is no guarantee that the product currently being developed will be able to successfully test for the virus.

QuestCap Inc (QSC) is down 8.11 per cent, with shares trading for $0.68 at 9:34am EST. 

More From The Market Herald
Featured Video Play Icon

" Sixth Wave (CSE:SIXW) announces rapid detection of E. Coli

Sixth Wave’s (SIXW) AMIPs prototype has detected E. Coli in as little as five minutes.

" Neovasc (TSX:NVCN) announces direct sales operations in the U.K.

Neovasc (NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022.
Lexagene Holdings - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) to host a webinar on the use of the MiQLab system to diagnose urinary tract infections

 LexaGene Holdings (LXG) and Dr. Jane Sykes will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.”
BriaCell Therapeutics Corp

" BriaCell (TSX:BCT) partners with Waisman Biomanufacturing

BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer.